A Tumor Cell-Selective Inhibitor of Mitogen-Activated Protein Kinase Phosphatases Sensitizes Breast Cancer Cells to

Christof T Kaltenmeier1, Laura L Vollmer1, Lawrence A Vernetti1

  • 1Departments of Surgery, Immunology and Biochemistry (C.T.K., M.T.L.), Drug Discovery Institute (L.L.V., L.A.V., L.C., K.D., M.T.L., A.V.), Department of Computational and Systems Biology (L.A.V., A.V.), Department of Pharmaceutical Sciences (V.N.K., B.W.D.), and Department of Developmental Biology (M.T.), University of Pittsburgh, Pittsburgh, Pennsylvania; and Platypus Technologies, LLC, Madison, Wisconsin (K.I.H.).

Insights

BCI-215, a novel compound, selectively kills cancer cells by activating mitogen-activated protein kinase (MAPK) signaling pathways, offering a potential new cancer therapy strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Dual specificity mitogen-activated protein kinase (MAPK) phosphatases (DUSP-MKPs) are implicated in cancer cell survival by regulating MAPK signaling.
  • Inhibiting DUSP-MKPs to hyperactivate MAPK signaling presents a potential strategy for cancer treatment.

Purpose of the Study:

  • To investigate the efficacy of BCI-215, a fibroblast growth factor signaling hyperactivator, in selectively targeting cancer cells.
  • To elucidate the molecular mechanisms underlying BCI-215's anti-cancer effects.

Main Methods:

  • In vivo structure-activity relationship studies in zebrafish.
  • In vitro experiments using MDA-MB-231 human breast cancer cells.
  • Kinase phosphorylation profiling and mechanistic studies.

Main Results:

  • BCI-215 demonstrated selective cytotoxicity in cancer cells, inhibiting motility and inducing apoptosis.
  • The compound activated extracellular signal-regulated kinase (ERK), p38, and c-Jun N-terminal kinase (JNK) signaling pathways.
  • BCI-215 sensitized cancer cells to immune cell killing and activated stress response pathways.

Conclusions:

  • BCI-215 selectively induces cancer cell death via non-redox-mediated MAPK pathway activation.
  • BCI-215's interaction with immune cell killing warrants further investigation for therapeutic development.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K